Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

NCT06651593 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: SAR444881
DRUG: Cemiplimab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]